Back to all studies
CompletedNCT03345979

Aripiprazole Lauroxil or Paliperidone Palmitate for schizophrenia

This study is completed in the United States. It is testing aripiprazole Lauroxil or Paliperidone Palmitate for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Aripiprazole Lauroxil or Paliperidone Palmitate may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Aripiprazole Lauroxil or Paliperidone Palmitate, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: November 15, 2017
Recruitment status
Completed
Enrollment listed in the registry
200
Sponsor
Alkermes, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
COMBINATION_PRODUCT, Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT03345979
Official title
A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 16 sites
  • Alkermes Investigational Site
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Rogers, Arkansas
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Cerritos, California
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Culver City, California
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Lemon Grove, California
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Hialeah, Florida
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Chicago, Illinois
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Hoffman Estates, Illinois
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Berlin, New Jersey
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Austin, Texas
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Garland, Texas
    Site status: Not listed — confirm with the team
  • Alkermes Investigational Site
    Richardson, Texas
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03345979. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Aripiprazole Lauroxil, Paliperidone Palmitate. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Alkermes, Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me